Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability.
Authors
J. Randolph Hecht
David Geffen School of Medicine at UCLA, Los Angeles, CA;
J. Randolph Hecht , Scott Kopetz , Theodore Welling , Maria Pia Morelli , Julian R. Molina , Kedar Kirtane , Paul Eliezer Oberstein , Daniel R. Greenwald , Yi Lin , Armen Mardiros , Karl Beutner , Ariane Lozac'hmeur , Ameen Salahudeen , Kirstin B. Liechty , Judy Vong , Eric Wai-Choi Ng , David G. Maloney , William Y. Go , John Sutton Welch , Diane M. Simeone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT04981119
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 209)
DOI
10.1200/JCO.2023.41.4_suppl.209
Abstract #
209
Poster Bd #
L11
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy.
First Author: Diane M. Simeone
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer/germline antigen in patients with squamous NSCLC or HNSCC.
First Author: George R. Blumenschein
Poster
2024 ASCO Breakthrough
Effect of heterozygosity loss of HLA-I on immune evasion and promotion of non-small cell lung cancer brain metastasis and immunotherapy resistance.
First Author: Jiefei Han